Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA-617

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 44, Issue 9, 2017, Pages 1448-1454

  Ahmadzadehfar, Hojjat ^a   Wegen, Simone ^a   Yordanova, Anna ^a   Fimmers, Rolf ^b   Kürpig, Stefan ^a   Eppard, Elisabeth ^a   Wei, Xiao ^a   Schlenkhoff, Carl ^a   Hauser, Stefan ^a   Essler, Markus ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

177Lu; Overall survival; Prostate cancer; Prostate specific membrane antigen; Response

Indexed keywords

LUTETIUM PROSTATE SPECIFIC MEMBRANE ANTIGEN 617 LU 177; PROSTATE SPECIFIC ANTIGEN; RADIOLIGAND; UNCLASSIFIED DRUG; DIPEPTIDE; LIGAND; LUTETIUM; LUTETIUM-177; PSMA-617; RADIOISOTOPE; SINGLE HETEROCYCLIC RINGS; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; FOLLOW UP; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; SURVIVAL ANALYSIS; TREATMENT RESPONSE; METABOLISM; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; DIPEPTIDES; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; LIGANDS; LUTETIUM; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RADIOISOTOPES; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 85019115377     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-017-3716-2     Document Type: Article

References (27)

1. Afshar-Oromieh A, Hetzheim H, Kratochwil C, Benesova M, Eder M, Neels OC, et al. The Theranostic PSMA ligand PSMA-617 in the diagnosis of prostate cancer by PET/CT: Biodistribution in humans, radiation dosimetry, and first evaluation of tumor lesions. Journal of nuclear medicine: official publication, Society of Nuclear Medicine. 2015;56:1697–705. doi:10.2967/jnumed.115.161299.
2. Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA, et al. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40:486–95. doi:10.1007/s00259-012-2298-2.
3. Rai BP, Baum RP, Patel A, Hughes R, Alonzi R, Lane T, et al. The role of positron emission tomography with (68)gallium (Ga)-labeled prostate-specific membrane antigen (PSMA) in the Management of Patients with Organ-Confined and Locally Advanced Prostate Cancer Prior to radical treatment and after radical prostatectomy. Urology. 2016;95:11–5. doi:10.1016/j.urology.2015.12.048.
4. Ahmadzadehfar H, Azgomi K, Hauser S, Wei X, Yordanova A, Gaertner F, et al. 68Ga-PSMA-11 PET as a gate-keeper for the treatment of metastatic prostate cancer with radium-223: proof of concept. Journal of nuclear medicine: official publication, Society of Nuclear Medicine. 2016; doi:10.2967/jnumed.116.178533.
5. Braat A, Ahmadzadehfar H. Lutetium-177 labelled PSMA ligands for the treatment of metastatic castrate-resistant prostate cancer. Tijdschr Nucl Geneesk. 2016;38:1627–34.
6. Ahmadzadehfar H, Eppard E, Kurpig S, Fimmers R, Yordanova A, Schlenkhoff CD, et al. Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer. Oncotarget. 2016;7:12477–88. doi:10.18632/oncotarget.7245.
7. Ahmadzadehfar H, Rahbar K, Kurpig S, Bogemann M, Claesener M, Eppard E, et al. Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study. EJNMMI Res. 2015;5:114. doi:10.1186/s13550-015-0114-2.
8. Rahbar K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, Schafers M, Essler M, et al. German multicenter study investigating 177Lu-PSMA-617 Radioligand therapy in advanced prostate cancer patients. Journal of nuclear medicine: official publication, Society of Nuclear Medicine. 2017;58:85–90. doi:10.2967/jnumed.116.183194.
9. Rahbar K, Schmidt M, Heinzel A, Eppard E, Bode A, Yordanova A, et al. Response and tolerability of a single dose of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: a multicenter retrospective analysis. Journal of nuclear medicine: official publication, Society of Nuclear Medicine. 2016;57:1334–8. doi:10.2967/jnumed.116.173757.
10. Kratochwil C, Giesel FL, Stefanova M, Benesova M, Bronzel M, Afshar-Oromieh A, et al. PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177Lu-labeled PSMA-617. Journal of nuclear medicine: official publication, Society of Nuclear Medicine. 2016;57:1170–6. doi:10.2967/jnumed.115.171397.
11. Rahbar K, Bode A, Weckesser M, Avramovic N, Claesener M, Stegger L, et al. Radioligand therapy with 177Lu-PSMA-617 as a novel therapeutic option in patients with metastatic castration resistant prostate cancer. Clin Nucl Med. 2016;41:522–8. doi:10.1097/RLU.0000000000001240.
12. Baum RP, Kulkarni HR, Schuchardt C, Singh A, Wirtz M, Wiessalla S, et al. 177Lu-labeled prostate-specific membrane antigen Radioligand therapy of metastatic castration-resistant prostate cancer: safety and efficacy. Journal of nuclear medicine: official publication, Society of Nuclear Medicine. 2016;57:1006–13. doi:10.2967/jnumed.115.168443.
13. Zechmann CM, Afshar-Oromieh A, Armor T, Stubbs JB, Mier W, Hadaschik B, et al. Radiation dosimetry and first therapy results with a (124)I/ (131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. Eur J Nucl Med Mol Imaging. 2014;41:1280–92. doi:10.1007/s00259-014-2713-y.
14. Ferdinandus J, Eppard E, Gaertner FC, Kurpig S, Fimmers R, Yordanova A, et al. Predictors of response to Radioligand therapy of metastatic castrate-resistant prostate cancer with 177Lu-PSMA-617. Journal of nuclear medicine: official publication, Society of Nuclear Medicine. 2017;58:312–9. doi:10.2967/jnumed.116.178228.
15. Rahbar K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, Schafers M, Essler M, et al. German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. Journal of nuclear medicine: official publication, Society of Nuclear Medicine. 2016; doi:10.2967/jnumed.116.183194.
16. Schlenkhoff CD, Gaertner F, Essler M, Schmidt M, Ahmadzadehfar H. Positive influence of 177Lu PSMA-617 therapy on bone marrow depression caused by metastatic prostate cancer. Clin Nucl Med. 2016;41:478–80. doi:10.1097/RLU.0000000000001195.
17. Schlenkhoff CD, Knupfer E, Essler M, Ahmadzadehfar H. Metastatic prostate cancer with restored Hormone-response after Radioligand therapy with 177Lu-PSMA-617. Clin Nucl Med. 2016;41:572–3. doi:10.1097/RLU.0000000000001200.
18. Wei X, Schlenkhoff C, Sopora C, Essler M, Ahmadzadehfar H. Successful treatment of hepatic metastases of Hormone refractory prostate cancer using Radioligand therapy with 177Lu-PSMA-617. Clin Nucl Med. 2016;41:894–5. doi:10.1097/RLU.0000000000001358.
19. Ahmadzadehfar H, Zimbelmann S, Yordanova A, Fimmers R, Kürpig S, Eppard E, et al. Radioligand therapy of metastatic prostate cancer using 177Lu-PSMA-617 after radiation exposure to 223Ra-dichloride. Oncotarget. 2017;
20. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187–97. doi:10.1056/NEJMoa1207506.
21. Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. The Lancet Oncology. 2015;16:152–60. doi:10.1016/S1470-2045(14)71205-7.
22. Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fossa SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213–23. doi:10.1056/NEJMoa1213755.
23. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376:1147–54. doi:10.1016/S0140-6736(10)61389-X.
24. Kantoff PW, Higano CS, Small EJ, Whitmore JB, Frohlich MW, Schellhammer PF. Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J Natl Cancer Inst. 2012;104:1107–1109; author reply 9-12. doi:10.1093/jnci/djs279.
25. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513–20. doi:10.1056/NEJMoa041318.
26. Kratochwil C, Giesel FL, Stefanova M, Benesova M, Bronzel M, Afshar-Oromieh A, et al. PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with Lu-177 labeled PSMA-617. Journal of nuclear medicine: official publication, Society of Nuclear Medicine. 2016; doi:10.2967/jnumed.115.171397.
27. Rahbar K, Schmidt M, Heinzel A, Eppard E, Bode A, Yordanova A, et al. Response and tolerability of a single dose of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: a multicenter retrospective analysis. Journal of nuclear medicine: official publication, Society of Nuclear Medicine. 2016; doi:10.2967/jnumed.116.173757.